The therapy targets CD19+ B cells, offering a new mechanism for managing this multiorgan fibroinflammatory disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback